$KLRA SEC Filings

Filed On	Filing
09 Sep 2026	Form 4: Nicholson Nur, Chief Technology Officer Granted 220,000 Stock Option (right to buy)
09 Sep 2026	Form 3: Nicholson Nur, Chief Technology Officer No securities owned
14 Aug 2026	SCHEDULE 13G
14 Aug 2026	SCHEDULE 13G
12 Aug 2026	10-Q
12 Aug 2026	8-K: Results of Operations and Financial Condition
05 Aug 2026	SCHEDULE 13G
08 Jul 2026	Form 4: Tregoning Kathleen, See Remarks Granted 175,000 Stock Option (right to buy)
08 Jul 2026	Form 3: Tregoning Kathleen, See Remarks No securities owned
11 Jun 2026	Form 4: Renaud Ronald C Jr, Director Received 38,094 shares by exercise or conversion ($200K)
26 May 2026	10-Q
26 May 2026	8-K: Results of Operations and Financial Condition
23 Apr 2026	SCHEDULE 13D
23 Apr 2026	SCHEDULE 13D
22 Apr 2026	Form 4: Rtw INVESTMENTS, Lp, 10% owner and 1 other Received 10,276,820 shares by conversion · Bought 500,000 shares ($8M)
22 Apr 2026	Form 4: Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% owner Received 11,511,852 shares by conversion
20 Apr 2026	Form 4: Bain Capital Investors Llc, 10% owner and 4 others Received 17,857,143 shares by conversion · Bought 8,398,438 shares ($134M)
20 Apr 2026	Form 4: Koppel Adam, Director Granted 38,300 Stock Option (right to buy) · Received 21,020,768 shares by conversion · Bought 1,562,500 shares ($25M)
20 Apr 2026	Form 4: Bain Capital Life Sciences Investors, Llc, 10% owner and 4 others Received 21,020,768 shares by conversion · Bought 1,562,500 shares ($25M)
20 Apr 2026	Form 4: Kaplan Andrew T., Director Granted 38,300 Stock Option (right to buy) · Received 17,857,143 shares by conversion · Bought 8,398,438 shares ($134M)

Comments